Protein OP-ORF Antibody

What are ORF proteins and why are antibodies against them important in research?

ORF proteins are encoded by open reading frames in genomic sequences and play critical roles in both viral and cellular processes. Antibodies targeting these proteins serve as essential tools for:

• Detection of viral infections: ORF virus (ORFV) F1L protein antibodies enable virus detection and study of pathogenesis mechanisms

• Serological diagnostics: SARS-CoV-2 ORF8 and ORF3b antibodies serve as accurate infection markers with 96.5% sensitivity and 99.5% specificity

• Cancer biomarkers: LINE-1 ORF1p antibodies detect protein expression in various cancer tissues while showing negative results in normal tissues

• Epitope mapping: Identification of specific antigenic regions, such as the 103CKSTCPKEM111 sequence in ORFV F1L protein

The development of specific ORF antibodies has significantly advanced our understanding of both pathogen biology and human disease mechanisms.

How do antibodies against different ORF proteins vary in their applications?

Different ORF protein antibodies have distinct research and clinical applications based on their target proteins:

This diversity highlights the importance of selecting the appropriate ORF protein antibody based on the specific research question being addressed.

What are the most effective methods for generating monoclonal antibodies against ORF proteins?

The development of high-quality monoclonal antibodies against ORF proteins typically follows these methodological steps:

• Antigen preparation:

  • Recombinant protein expression using prokaryotic systems (e.g., for ORFV F1L)

  • Synthetic peptides corresponding to specific regions of interest

  • Purified viral particles or protein fragments

• Immunization protocol:

  • BALB/c mice immunization with purified antigen

  • Multiple boosting injections to enhance immune response

  • Monitoring of antibody titer development

• Hybridoma generation and selection:

  • Fusion of splenocytes with myeloma cells

  • Screening using indirect ELISA to identify positive clones

  • Multiple rounds of subcloning (typically 3) to ensure monoclonality

• Validation:

  • Western blot to confirm specificity for target protein

  • Immunofluorescence assay (IFA) to verify recognition of native protein

  • Cross-reactivity testing against related proteins

For example, the Ba-F1L monoclonal antibody was generated through immunization with prokaryotically expressed F1L protein, followed by three rounds of subcloning, resulting in an antibody that specifically recognized both recombinant and native F1L protein .

How can researchers identify and characterize linear B-cell epitopes on ORF proteins?

Identification of linear B-cell epitopes on ORF proteins involves several methodological approaches:

• Truncation mapping:

  • Generate a series of truncated protein fragments

  • Express these fragments in eukaryotic cells

  • Test antibody reactivity via Western blot

  • Narrow down the minimal sequence required for antibody recognition

• Peptide-based approaches:

  • Synthesize overlapping peptides spanning the target protein

  • Create peptide arrays for high-throughput screening

  • Test antibody binding to identify specific reactive peptides

• Confirmation and characterization:

  • Alanine scanning mutagenesis to identify critical residues

  • Homology analysis across strains to assess epitope conservation

  • Structural prediction to determine epitope accessibility

The identification of the 103CKSTCPKEM111 epitope in ORFV F1L protein demonstrates the utility of these approaches. This epitope was found to be highly conserved across ORFV strains, making it an excellent target for universal diagnostic applications .

How are ORF protein antibodies used in cancer research and diagnostics?

ORF protein antibodies have emerged as powerful tools in cancer research, particularly for studying retrotransposon-derived proteins:

• Detection of LINE-1 ORF1p expression:

  • Immunohistochemistry reveals strong cytoplasmic staining in various cancer tissues (colon, pancreatic, lung) but negative staining in adjacent normal tissues

  • Western blot detects bands at 42 kDa (full-length) and 33 kDa (truncated form)

  • Flow cytometry distinguishes between high-expressing cells (NCCIT) and low-expressing cells (HCT 116)

• Mechanistic studies:

  • LINE-1 ORF1p overexpression reduces drug sensitivity by increasing IC50 values:

  Drug	IC50 (Control)	IC50 (ORF1p Overexpression)	IC50 (ORF1p Knockdown)
  Epirubicin	36.04 nmol/L	59.11 nmol/L	3.83 nmol/L
  Cisplatin	37.94 nmol/L	119.32 nmol/L	2.89 nmol/L
  Paclitaxel	35.90 nmol/L	No significant change	7.36 nmol/L

  • Western blot analysis shows ORF1p modulates expression of MDR, p-gp, p53, and Bcl-2 proteins

• Biomarker development:

  • Detection of LINE-1 ORF1p in conditioned media, ascites, and patient plasma samples using immuno-multiple reaction monitoring-mass spectrometry

  • Expression in fallopian tube epithelial precursors of high-grade serous ovarian carcinoma, suggesting potential as an early disease marker

These applications demonstrate the versatility of ORF protein antibodies in understanding cancer mechanisms and developing diagnostic approaches.

What roles do ORF protein antibodies play in infectious disease research?

ORF protein antibodies serve critical functions in infectious disease research, particularly for viral diagnostics and pathogenesis studies:

• Serological diagnostics:

  • SARS-CoV-2 ORF8 and ORF3b antibodies provide highly accurate infection detection:

    • Combined sensitivity: 96.5% for COVID-19 samples

    • Specificity: 99.5% (no cross-reactivity with common-cold HCoVs)

  • Stable antibody levels observed up to 100 days post-symptom onset

• Virus detection and characterization:

  • ORFV086 monoclonal antibody (5F2D8) recognizes multiple bands (100, 70, and 20 kDa) from viral lysate

  • Strong reactivity with different field isolates of orf viruses from China

  • Possesses virus-neutralizing capability

• Pathogenesis studies:

  • Antibodies against ORF virus F1L protein enable study of viral adsorption and entry mechanisms

  • F1L protein identified as participating in viral binding to heparin

  • Potential applications in subunit vaccine development

These applications highlight how ORF protein antibodies facilitate both clinical diagnostics and fundamental research into disease mechanisms.

What strategies can overcome detection challenges for low-abundance ORF proteins?

Detecting low-abundance ORF proteins presents significant technical challenges requiring specialized approaches:

• Enhanced enrichment techniques:

  • Immunoprecipitation with highly specific antibodies

  • Subcellular fractionation to concentrate target proteins

  • Sequential affinity purification for multi-epitope proteins

• Targeted mass spectrometry approaches:

  • Selected Reaction Monitoring (SRM) or Parallel Reaction Monitoring (PRM)

  • Detection sensitivity down to ~10 attomoles

  • Implementation on triple quadrupole or quadrupole-Orbitrap instruments

• Validation strategies:

  • shRNA knockdown to confirm specificity (e.g., LINE-1 knockdown in N2102Ep cells)

  • Mass spectrometry-based peptide sequencing to verify target identity

  • Absence in normal tissues and presence in disease tissues as biological validation

These approaches have been successfully applied to detect endogenous LINE-1 ORF2p, which is present at approximately 3 orders of magnitude lower concentration than ORF1p in cell extracts, making it undetectable by standard Western blotting or shotgun mass spectrometry even after affinity enrichment .

How can antibody cross-reactivity issues be identified and mitigated in ORF protein research?

Cross-reactivity represents a significant challenge in ORF protein research due to sequence similarities between different proteins:

• Identification strategies:

  • BLAST searches of presumed antibody target epitopes against the proteome

  • Shotgun proteomics of immunoprecipitated material to identify co-purifying proteins

  • Testing antibody reactivity in cells with target protein knockout or knockdown

• Case example: LINE-1 ORF2p antibody (clone 9) cross-reactivity:

  • L1TD1 protein was consistently among the most abundant proteins in anti-ORF2p immunoprecipitations

  • BLAST search revealed a close partial match between the antibody target epitope in ORF2p (333KASRRQEITKIRAE346) and an L1TD1 epitope (501KASRRQKEI509)

  • Despite this cross-reactivity, the antibody could still enrich genuine ORF2p in the presence of competing epitopes

• Validation requirements:

  • Secondary validation using orthogonal methods (e.g., MS-based peptide sequencing)

  • Target protein knockdown coupled with antibody detection

  • Comparison of signals between known positive and negative tissues

The study of LINE-1 ORF2p emphasizes that claims of endogenous ORF2p detection without robust secondary validation (particularly MS-based peptide sequencing) should be viewed skeptically .

What computational approaches enable the rational design of antibodies against specific ORF protein epitopes?

Rational antibody design offers powerful alternatives to traditional hybridoma approaches for targeting specific ORF protein epitopes:

• OptCDR (Optimal Complementarity Determining Regions):

  • Uses canonical structures to generate CDR backbone conformations

  • Predicts favorable interactions with target antigen

  • Amino acids selected for each position using rotamer libraries

  • Undergoes multiple iterations to refine sequences

• Disordered epitope targeting:

  • Sequence-based design of complementary peptides for selected epitopes

  • Grafting designed peptides onto antibody scaffolds

  • Particularly effective for targeting intrinsically disordered regions

  • Successfully applied to disease-related disordered proteins

• Key mutation strategies for increasing affinity:

  • Elimination of residues with unsatisfied polar groups in CDRs

  • Introduction or removal of charged residues at peripheral CDR sites

  • Mutation of small hydrophobic residues at appropriate positions

These computational approaches have been tested on various targets including hepatitis C virus capsid peptides, fluorescein, and vascular endothelial growth factor (VEGF), demonstrating their potential for developing antibodies against challenging ORF protein targets .

How are modular antibody architectures being applied to ORF protein targeting?

Recent advances in modular antibody design have expanded possibilities for ORF protein targeting:

• Antibody nanocages (AbCs):

  • Designed proteins drive assembly of antibody nanocages with controlled architecture

  • Components include antibody Fc-binding domains, helical repeat connectors, and cyclic oligomer-forming modules

  • Enables precise control of antibody valency and spatial arrangement

• Geometric design approaches:

  • Computational fusion of protein building blocks with cyclic symmetry

  • Alignment of building block symmetry axes with target architecture

  • Tripartite fusions (Fc-binder–connector–homo-oligomer) created through rigid helical fusion

• Advantages for ORF protein targeting:

  • Enhanced binding avidity through multivalent presentation

  • Incorporation of different receptor-engaging antibodies in same structure

  • Potential for cargo delivery to specific cell types

  • Structural homogeneity for precise tuning of biological effects

These modular approaches represent promising strategies for developing next-generation antibody therapeutics and research tools targeting ORF proteins in viral infections and cancer.